About Us

Company Profile

Management Team

Investors

Scientific Advisor

Contact Us

Our Approach

Why ADC？

Duality Novel Platforms

Pipeline

Globally Competitive Product Pipeline

Expanded Access Policy

Media

Corporate News

Industry Dynamics

Partnership

Collaboration Model

Collaboration Cases

Careers

Corporate Culture

Job Opportunities

MEDIA
MEDIA
Corporate News
Industry Dynamics
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
2023-08-07
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
2023-07-10
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline
2023-05-30
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
2023-04-03
DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)
DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)
2023-01-29
Strategic Collaboration｜Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
Strategic Collaboration｜Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
2023-01-05
Enterprise Honor
Enterprise Honor
2023-03-09
Duality Biologics Completed $90 Million Series B Financing
Duality Biologics Completed $90 Million Series B Financing
2021-05-20
Strategic Collaboration｜Duality Biologics and Harbour BioMed reached a strategic collaboration agreement
Strategic Collaboration｜Duality Biologics and Harbour BioMed reached a strategic collaboration agreement
2022-01-24
Duality Biologics is awarded as 2020 SIPAC (Suzhou Industrial Park) Key Leading Talent Programme
Duality Biologics is awarded as 2020 SIPAC (Suzhou Industrial Park) Key Leading Talent Programme
2021-05-06
Strategic Collaboration｜Duality Biologics and Sinotau Pharmaceuticals reached a strategic collaboration agreement
Strategic Collaboration｜Duality Biologics and Sinotau Pharmaceuticals reached a strategic collaboration agreement
2021-12-20
Our First Team Building Activties
Our First Team Building Activties
2021-09-01